<!DOCTYPE html>

<html lang="en">

        <head>
                <!-- Page information -->
                <meta charset="UTF-8" />
                <meta name="node_id" content="Chronic Obstructive Pulmonary Disease">
                <meta name="viewport" content="width=device-width, initial-scale=1.0" />
                <link rel="shortcut icon" href="/favicon.ico" />

                <!-- Set title -->
                <title>Pulmonary Critical Care Notes</title>

                <!-- Includes -->
                <link rel="stylesheet" href="/obs.html/static/global_main.css" />
                <link rel="stylesheet" href="/obs.html/static/main.css" />
                
<script src="/obs.html/static/obsidian_core_header.js"></script>
<script src="/obs.html/static/encoding.js"></script>
<link rel="stylesheet" href="/obs.html/static/callouts.css" />
<link rel="stylesheet" href="/obs.html/static/graph.css" />
<link rel="stylesheet" href="/obs.html/static/codehilite.css" />
<link rel="stylesheet" href="/obs.html/static/mermaid.css" />
<script src="/obs.html/static/mermaid.9.0.1.min.js"></script>
<script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
<script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-chtml.js"></script>
<script src="/obs.html/static/load_mathjax.js"></script>
<link rel="stylesheet" href="/obs.html/static/search.css" />
<script src="https://cdn.jsdelivr.net/gh/nextapps-de/flexsearch@0.7.2/dist/flexsearch.bundle.js"></script>
<script src="/obs.html/static/pako.js"></script>
<script src="/obs.html/static/search.js"></script>
<script src="/obs.html/static/dirtree.js"></script>


                <!-- Onload tweaks -->
                <script>
                        const CURRENT_NODE = 'Chronic Obstructive Pulmonary Disease';
                </script>
        </head>

<body onload="LoadPage();">

        <div id="search-master-div">
    <div id="search-slab" king_ramses="return the slaaab">
            <div id="search-controls">
                    <input id="search_string" placeholder="Type to search notes" type="text" />
                    <div class="tooltip" style="display: none;">
                        <input type="checkbox" id="hard_search" name="hard" />
                        <span class="tooltiptext">Hard search (require exact match)</span>
                    </div>
                    <div id="search-results-box">
                        <div id="search-results"></div>
                    </div>
                    <div id="search-instructions">
                        <div class="prompt-instruction">
                                <b>esc</b> to dismiss
                        </div>
                    </div>
            </div>
    </div>
</div>

<script>
    document.getElementById("search-master-div").addEventListener('click', e => {
            if(e.target !== e.currentTarget){
                    return
            }
            toggle('search-master-div', 'block');
    })
    document.getElementById("search_string").addEventListener("input", function(event) {
            setTimeout( () =>run_search('search_string', 'hard_search'), 100 );
    }); 
    document.getElementById("hard_search").addEventListener("click", function(event) {
            setTimeout( () =>run_search('search_string', 'hard_search'), 100 );
    });

    window.addEventListener('keydown', e => {
        if((e.key=='Escape'||e.key=='Esc'||e.keyCode==27)){
            document.getElementById('search-master-div').style.display = 'none';
            return false;
        } 
    }, true);

    function click_list_link(element){
        element.parentElement.getElementsByTagName('a')[0].click()
    }
</script>


        <div class="flex_col">
                <div id="header" class="header">
                        <div id="header_flex" class="flex_row">
                                <a href="/index.html" id="homelink" title="Clear screen and go to homepage">Pulmonary Critical Care Notes</a>
                                <div class="navbar-button" onclick="toggle('navbar', 'flex')">
                                        ≡
                                </div>
                                <div id="navbar" class="navbar">
                                <a class="navbar-link" href="/Pulmonary Medicine/Pulmonary Medicine.html" title="Pulmonary">Pulmonary</a>
<a class="navbar-link" href="/Critical Care Medicine/Critical Care Medicine.html" title="Critical Care">Critical Care</a>
                                        <div class="icon-tray">
                                                
                                                <div style="width:1.6rem; height:1.6rem; float:right; margin-right:0.2rem">
                                                        <a href="/obs.html/tags/index.html" title="Open tag view">
                                                                <img src = "/obs.html/static/hashtag.svg" alt="RSS Feed link"/>
                                                        </a>
                                                </div>
                                                        <div style="width: calc(1.6rem - 6px); height: calc(1.6rem - 6px); border: 3px solid #f0f0f0; margin-right:0.2rem; float:right;">
            <a id="dirtree_link" class="system-link" href="/obs.html/dir_index.html" title="View directory tree">
                    <img src = "/obs.html/static/dirtree.svg" style="width: 14px; padding: 3px;" alt="Directory tree link"/>
            </a>
        </div>
                                                        <div class="graph_header_div">
            <a id="graph_link" class="system-link" href="/obs.html/graph/index.html?node=Chronic Obstructive Pulmonary Disease" title="Open fullpage Graph">
                    <img class="graph_header_div_svg" src = "/obs.html/static/graph.svg" alt="Open fullpage Graph"/>
            </a>
        </div>
                                                        <div onclick="openSearch()" style="width: calc(1.6rem - 12px); height: calc(1.6rem - 12px); border: 3px solid #f0f0f0; margin-right:0.2rem; float:right; padding: 3px; padding-bottom: 6px; padding-top: 0px;cursor: pointer;">
                <img src = "/obs.html/static/search.svg" alt="Search notes"/>
        </div>
        <script>
                function openSearch(){
                        if (toggle('search-master-div', 'block')){
                                let ss = document.getElementById('search_string');
                                ss.value = '';
                                ss.focus()
                                ss.select()
                        }
                }
        </script>
                                        </div>
                                </div>
                        </div>
                </div>
                <div class="flex_row">
                        <div id="left_pane"></div>
                        <div class="container">
                                        <h1 id="general-information">General Information</h1>
<div class="toc">
<ul>
<li><a href="#general-information" class="anchor-link">General Information</a></li>
<li><a href="#associated-anatomy-physiology" class="anchor-link">Associated Anatomy &amp; Physiology</a></li>
<li><a href="#associated-histology" class="anchor-link">Associated Histology</a></li>
<li><a href="#epidemiology" class="anchor-link">Epidemiology</a><ul>
<li><a href="#burden-of-copd" class="anchor-link">Burden of COPD</a><ul>
<li><a href="#copd-is-underdiagnosed-and-under-reported" class="anchor-link">COPD is underdiagnosed and under-reported</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="#etiology-pathogenesis-pathology" class="anchor-link">Etiology, Pathogenesis &amp; Pathology</a><ul>
<li><a href="#etiology-risk-factors" class="anchor-link">Etiology &amp; Risk Factors</a><ul>
<li><a href="#lung-function-trajectory" class="anchor-link">Lung Function Trajectory</a></li>
<li><a href="#dysanapsis" class="anchor-link">Dysanapsis</a></li>
<li><a href="#risk-factors-for-aecopd" class="anchor-link">Risk Factors for AECOPD</a></li>
<li><a href="#etiology-of-aecopd" class="anchor-link">Etiology of AECOPD</a></li>
</ul>
</li>
<li><a href="#pathogenesis" class="anchor-link">Pathogenesis</a><ul>
<li><a href="#inflammation-in-copd" class="anchor-link">Inflammation in COPD</a><ul>
<li><a href="#t-lymphocytes" class="anchor-link">T Lymphocytes</a></li>
<li><a href="#neutrophils" class="anchor-link">Neutrophils</a></li>
<li><a href="#macrophages" class="anchor-link">Macrophages</a></li>
<li><a href="#b-lymphocytes" class="anchor-link">B Lymphocytes</a></li>
<li><a href="#inflammatory-mediators" class="anchor-link">Inflammatory Mediators</a></li>
<li><a href="#protease-and-antiprotease-imbalance" class="anchor-link">Protease and Antiprotease Imbalance</a></li>
<li><a href="#hdac-expression-is-reduced-in-copd" class="anchor-link">HDAC expression is reduced in COPD</a></li>
</ul>
</li>
<li><a href="#-1-antitrypsin-aat-deficiency" class="anchor-link">α-1 Antitrypsin (AAT) Deficiency</a></li>
<li><a href="#exacerbation-prone-copd" class="anchor-link">Exacerbation-Prone COPD</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="#pathophysiology" class="anchor-link">Pathophysiology</a><ul>
<li><a href="#mucus-hypersecretion-ciliary-dysfunction" class="anchor-link">Mucus Hypersecretion &amp; Ciliary Dysfunction</a><ul>
<li><a href="#mucus-hypersecretion" class="anchor-link">Mucus Hypersecretion</a></li>
<li><a href="#ciliary-dysfunction" class="anchor-link">Ciliary Dysfunction</a></li>
</ul>
</li>
<li><a href="#airflow-limitation-air-trapping-hyperinflation" class="anchor-link">Airflow Limitation &amp; Air Trapping (Hyperinflation)</a></li>
<li><a href="#emphysema-gas-exchange-abnormalities" class="anchor-link">Emphysema &amp; Gas Exchange Abnormalities</a><ul>
<li><a href="#subtypes-of-emphysema" class="anchor-link">Subtypes of Emphysema</a></li>
<li><a href="#gas-exchange-abnormalities" class="anchor-link">Gas Exchange Abnormalities</a></li>
</ul>
</li>
<li><a href="#pulmonary-hypertension" class="anchor-link">Pulmonary Hypertension</a></li>
<li><a href="#systemic-effects" class="anchor-link">Systemic Effects</a></li>
<li><a href="#exacerbation-pathophysiology" class="anchor-link">Exacerbation Pathophysiology</a></li>
</ul>
</li>
<li><a href="#history-physical-examclinical-features" class="anchor-link">History &amp; Physical Exam/Clinical Features</a></li>
<li><a href="#diagnosis" class="anchor-link">Diagnosis</a><ul>
<li><a href="#consider-copd-and-perform-spirometry-if" class="anchor-link">Consider COPD and Perform Spirometry if:</a></li>
<li><a href="#gold-grades" class="anchor-link">GOLD Grades</a></li>
<li><a href="#symptom-assessment-tool" class="anchor-link">Symptom Assessment Tool</a><ul>
<li><a href="#mmrc-dyspnea-scale" class="anchor-link">mMRC Dyspnea Scale</a></li>
<li><a href="#copd-assessment-tool-cat" class="anchor-link">COPD Assessment Tool (CAT)</a></li>
</ul>
</li>
<li><a href="#additional-investigations-to-consider" class="anchor-link">Additional Investigations to Consider</a></li>
<li><a href="#diagnosis-of-aecopd" class="anchor-link">Diagnosis of AECOPD</a></li>
</ul>
</li>
<li><a href="#management" class="anchor-link">Management</a><ul>
<li><a href="#management-of-stable-copd" class="anchor-link">Management of Stable COPD</a><ul>
<li><a href="#pharmacologic-therapy" class="anchor-link">Pharmacologic Therapy</a></li>
<li><a href="#non-pharmacologic-therapy" class="anchor-link">Non-Pharmacologic Therapy</a></li>
</ul>
</li>
<li><a href="#management-of-acute-exacerbations" class="anchor-link">Management of Acute Exacerbations</a></li>
</ul>
</li>
<li><a href="#complication-prognosis" class="anchor-link">Complication &amp; Prognosis</a><ul>
<li><a href="#comorbidities-4e379d" class="anchor-link">Comorbidities ^4e379d</a><ul>
<li><a href="#impact-on-mortality" class="anchor-link">Impact on Mortality</a></li>
<li><a href="#frequent-exacerbations-decline-in-lung-function" class="anchor-link">Frequent Exacerbations &amp; Decline in Lung Function</a></li>
<li><a href="#copd-exacerbations-impact-survival" class="anchor-link">COPD Exacerbations Impact Survival</a></li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<ul>
<li>Definition: <strong>persistent airflow limitation</strong> that is usually progressive and is associated with a chronic enhanced inflammatory response in the airways and lungs to noxious particles and gases   <ul>
<li>due to airway and/or alveolar abnormalities   </li>
</ul>
</li>
<li>Common, preventable &amp; treatable disease   </li>
<li>Usually caused by significant exposure to noxious particles or gases   <ul>
<li>Developed countries — smoking; developing countries — biomass fuel   </li>
</ul>
</li>
<li>Influenced by host factors including abnormal lung development   </li>
<li>Chronic bronchitis — clinical diagnosis — chronic <a href="/not_created.html" class="nonexistent-link">cough</a> and sputum production   <ul>
<li>epidemiological definition — chronic productive <a href="/not_created.html" class="nonexistent-link">cough</a> on most days during at least 3 months per year for 2 or more consecutive years   </li>
<li>periods of worsening or exacerbation precipitated by a respiratory tract infection   </li>
<li>in between exacerbations, residual clinical disease (unlike asthma where symptoms go away in between exacerbations) because chronic bronchitis is not a disease of airway hyperreactivity   </li>
<li>If clinical features of chronic bronchitis with evidence of airway hyperreactivity → asthmatic bronchitis or asthma-COPD overlap syndrome   </li>
</ul>
</li>
<li>Emphysema — pathological diagnosis — destruction of lung parenchyma and enlargement of air spaces distal to the terminal bronchiole — this is the region from respiratory bronchioles to the alveoli   <ul>
<li>where the destruction is along this path determines the subtype of emphysema   </li>
</ul>
</li>
<li>Chronic bronchitis and emphysema can (and often do) co-exist in a patient therefore the broader term of COPD is used   </li>
<li>Significant comorbidities may have an impact on morbidity and mortality   </li>
</ul>
<h1 id="associated-anatomy-physiology">Associated Anatomy &amp; Physiology</h1>
<h1 id="associated-histology">Associated Histology</h1>
<h1 id="epidemiology">Epidemiology</h1>
<h2 id="burden-of-copd">Burden of COPD</h2>
<h3 id="copd-is-underdiagnosed-and-under-reported">COPD is underdiagnosed and under-reported</h3>
<ul>
<li>Prevalence estimates vary widely   <ul>
<li>Global -- 10.1%   </li>
</ul>
</li>
<li>Deaths -- 3.2 million annually   <ul>
<li>Third leading cause of death worldwide   </li>
</ul>
</li>
<li>Prevalence expected to rise over next 4 decades   </li>
<li>Prevalence increasing in women   </li>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503101718.png" />   <ul>
<li>China and India account for more than 50% of all cases of COPD in the world   </li>
</ul>
</li>
<li>Undiagnosed COPD   <ul>
<li>Percentage of undiagnosed COPD in the general population, aged 40 or older with current or past exposure to tobacco (≥10 pack-years) is 70-78%   </li>
<li>Overall health system burden by undiagnosed COPD still exists and its largely unrecognized   </li>
<li>Asymptomatic Undiagnosed COPD   <ul>
<li>If FEV₁ &lt;80% (moderate or more severe obstruction) → adverse effects ~ symptomatic COPD   </li>
<li>Increased risk of exacerbations and pneumonia   </li>
</ul>
</li>
<li>Symptomatic Undiagnosed COPD   <ul>
<li>increased risk of exacerbations, pneumonia and death   </li>
</ul>
</li>
<li>i.e. it doesn't matter if they are symptomatic or not, being undiagnosed increases risk of adverse effects   </li>
</ul>
</li>
</ul>
<h1 id="etiology-pathogenesis-pathology">Etiology, Pathogenesis &amp; Pathology</h1>
<h2 id="etiology-risk-factors">Etiology &amp; Risk Factors</h2>
<ul>
<li>Early life factors and exposures   <ul>
<li>Maternal smoking   </li>
<li>Respiratory infections   </li>
<li>Dysanapsis (Mismatch of airway tree caliber to lung size; develops early in life)   </li>
</ul>
</li>
<li>Tobacco smoke   <ul>
<li>Nearly 80% of all COPD cases can be attributed to smoking   </li>
<li><strong>15-20% of 1 pack per day (PPD) smokers and 25% of 2 PPD smokers will develop COPD</strong>   </li>
</ul>
</li>
<li>Outdoor and Indoor Pollution   <ul>
<li>Biomass fuel   <ul>
<li><strong>50% of COPD deaths in developing countries are from biomass smoke</strong>   </li>
<li>75% are in women   </li>
</ul>
</li>
</ul>
</li>
<li>Occupational exposures   <ul>
<li>May account for 15-20% of COPD   </li>
<li><strong>Mining</strong>, agriculture, textile, paper, wood, chemical, food processing   </li>
<li><strong>Cadmium fumes can cause emphysema (smelting, batteries)</strong>   </li>
</ul>
</li>
<li>Socioeconomic status   </li>
<li>Genetic factors   <ul>
<li>Several GWAS (genome-wide association study) have linked genetic loci with COPD but causality remains uncertain   </li>
<li><strong>Best documented in Alpha-I Antitrypsin Deficiency</strong>   <ul>
<li><strong><em>SERPINA1</em></strong> gene mutation   </li>
</ul>
</li>
</ul>
</li>
</ul>
<h3 id="lung-function-trajectory">Lung Function Trajectory</h3>
<ul>
<li>Reduced maximal attained lung function may identify individuals at increased risk   </li>
<li>Incidence of COPD was higher when FEV1 was &lt;80% predicted before age 40 (26% vs 7%; P &lt;0.001)   </li>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503102438.png" />   <ul>
<li>TR1: Normal   </li>
<li>TR2: Small lungs but no COPD   </li>
<li>TR3: Normal initial FEV₁ with rapid decline leading to COPD   </li>
<li>TR4: Small lungs leading to COPD   </li>
</ul>
</li>
</ul>
<h3 id="dysanapsis">Dysanapsis</h3>
<ul>
<li>Associated with incident COPD in older adults   </li>
<li>Develops early in life    </li>
<li>May contribute to COPD susceptibility later in life   </li>
<li>Three trials -- MESA (N=2531), CanCOLD (N=1272), SPIROMICS (N=2726)   </li>
<li>Incidence and prevalence of COPD was highest in the lowest airway to lung ratio quartiles in MESA and CanCOLD   </li>
<li>SPIROMICS participants with COPD in the highest airway to lung ratio quartiles had faster FEV₁ decline as compared to the lowest airway to lung ratio quartile suggesting two different paths for COPD development   </li>
<li>Can lead to <a href="/Pulmonary Medicine/01. Diseases of the Airways/Index/Tracheobronchial Diseases.html#bronchopulmonary-dysplasia">Bronchopulmonary Dysplasia</a>   </li>
</ul>
<h3 id="risk-factors-for-aecopd">Risk Factors for AECOPD</h3>
<ul>
<li>Advanced age   </li>
<li>Severity of airflow limitation   </li>
<li>Chronic mucous hypersecretion   </li>
<li>Productive <a href="/not_created.html" class="nonexistent-link">cough</a>   </li>
<li>Duration of COPD   </li>
<li>Pulmonary Hypertension (Pulmonary Artery {PA}: Ascending Aorta {A} ratio &gt;1)   </li>
<li>Blood eosinophil count &gt;340 cells/μL   </li>
<li><a href="/Pulmonary Medicine/01. Diseases of the Airways/Chronic Obstructive Pulmonary Disease.html#^4e379d">Comorbid Conditions</a>   </li>
<li>GERD   </li>
<li>History of antibiotic use   </li>
<li>COPD-related hospitalization in the previous year   <ul>
<li><strong>History of prior exacerbations is the single best predictor, regardless of severity</strong>   </li>
</ul>
</li>
</ul>
<h3 id="etiology-of-aecopd">Etiology of AECOPD</h3>
<ul>
<li>Causes of exacerbations requiring hospitalization in patients (Papi A, et al. Am J Respir Crit Care Med. 2006;173:1114)   <ul>
<li>Non-infectious 21.8%   </li>
<li>Bacteria 29.7%   </li>
<li>Virus 23.4%   </li>
<li>Bacteria &amp; Virus 25%   </li>
</ul>
</li>
</ul>
<h2 id="pathogenesis">Pathogenesis</h2>
<ul>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503104055.png" />   </li>
</ul>
<h3 id="inflammation-in-copd">Inflammation in COPD</h3>
<ul>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503104157.png" />   </li>
</ul>
<h4 id="t-lymphocytes">T Lymphocytes</h4>
<ul>
<li>Increase in T lymphocytes in the airway wall and lung parenchyma   <ul>
<li>organize into lymphoid follicles   </li>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503104319.png" />   <ul>
<li>Collection of bronchial lymphoid tissue with a lymphoid follicle containing a germinal center (GC) surrounded by a rim of darker-staining lymphocytes that extend to the epithelium of both the small airway and alveolar surface   </li>
</ul>
</li>
<li>Shift in the balance of CD4/CD8 T cell ratio in favor of CD8 → direct toxic effects → alveolar wall destruction   </li>
</ul>
</li>
<li>Number of Th1 and Tc1 cells, which produce interferon-γ increase   </li>
</ul>
<h4 id="neutrophils">Neutrophils</h4>
<ul>
<li>Release proteases   </li>
<li>Increased in the sputum and distal airspaces of smokers   </li>
<li>Further increase occurs in COPD and is related to disease severity   </li>
</ul>
<h4 id="macrophages">Macrophages</h4>
<ul>
<li>Produce inflammatory mediators and proteases   </li>
<li>Increased in number in airway, lung parenchyma and in BAL fluid   </li>
</ul>
<h4 id="b-lymphocytes">B Lymphocytes</h4>
<ul>
<li>increased in peripheral airways and within lymphoid follicles possibly as a response to chronic infection of the airways   </li>
</ul>
<h4 id="inflammatory-mediators">Inflammatory Mediators</h4>
<ul>
<li>Leukotriene B4   <ul>
<li>Chemoattractant of neutrophils and T cells   </li>
<li>produced by macrophages, neutrophils, and epithelial cells   </li>
</ul>
</li>
<li>Chemotactic factors (CXC) &amp; Chemokines (IL-8 &amp; growth related oncogene α)   <ul>
<li>produced by macrophages and epithelial cells   </li>
<li>Chemoattractant of cells from circulation and amplify pro-inflammatory responses   </li>
</ul>
</li>
<li>TNF-α &amp; IL 1β + IL 6 -- Pro-inflammatory cytokines   </li>
<li>TGF-β -- growth factors   <ul>
<li>may cause fibrosis in the airways either directly or through release of another cytokine, connective tissue growth factor   </li>
</ul>
</li>
</ul>
<h4 id="protease-and-antiprotease-imbalance">Protease and Antiprotease Imbalance</h4>
<ul>
<li>Increased production (or activity) of proteases and decreased production (or inactuvation) of antiproteases = imbalance   </li>
<li>Cigarette smoke + inflammation → oxidative stress → primes inflammatory cells → release of proteases and inactivates several antiproteases by oxidation   <ul>
<li>Oxidative stress   <ul>
<li>leads to inactivation of antiproteases &amp; stimulation of mucous production   </li>
<li>Amplifies inflammation by enhancing transcription factor activation (NFκB) → gene expression of pro-inflammatory mediators   </li>
</ul>
</li>
</ul>
</li>
<li>Main proteases involved   <ul>
<li>Neutrophil produced -- serine proteases, elastase, cathepsin G, and protease 3   </li>
<li>Macrophage produced -- cysteine proteases, cathepsins E, A, L, and S   </li>
<li>Matrix metalloproteases -- MMP-8, MMP-9, and MMP-12   </li>
</ul>
</li>
<li>Main antiproteases involved   <ul>
<li>α1 antitrypsin   </li>
<li>secretory leukoprotease inhibitor   </li>
<li>tissue inhibitors of metalloproteases   </li>
</ul>
</li>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/2022-05-03%20COPD02.f7.jpg" />   </li>
</ul>
<h4 id="hdac-expression-is-reduced-in-copd">HDAC expression is reduced in COPD</h4>
<ul>
<li>Histone deacetylase 2 (HDAC2 suppresses inflammatory gene experssion   </li>
<li>Corticosteroids can recruit HDAC and reverse inflammatory process   </li>
<li>HDAC function is impaired by cigarette smoking and oxidative/nitrative stress   </li>
<li>HDAC levls in the lung decrease with increasing COPD severity   </li>
<li>In COPD, there is decreased corticosteroid responsiveness   </li>
</ul>
<h3 id="-1-antitrypsin-aat-deficiency">α-1 Antitrypsin (AAT) Deficiency</h3>
<ul>
<li>AAT is a protease inhibitor of the proteolytic enzyme elastase   </li>
<li>An imbalance between neutrophil elastase and the elastase inhibitor causes early COPD in smokers (see above)   </li>
<li>COPD occurs later in non-smokers   </li>
<li>Inherited in autosomal co-dominant pattern   <ul>
<li>SERPINA1 gene on Chromosome 14   </li>
<li>M allele is normal   </li>
<li>S or Z allele a/w deficiency   </li>
</ul>
</li>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503104924.png" />   </li>
<li>Consider AAT if   <ul>
<li>earlier age of onset (&lt;45 years)   </li>
<li>emphysema in a nonsmoker or minimal smoker   </li>
<li>Basal, pan-acinar emphysema   </li>
<li>Unremitting asthma with persistent airflow limitation   </li>
<li>Concurrent liver disease/cirrhosis   </li>
<li>Necrotizing panniculitis   </li>
<li>C-ANCA positive vasculitis   </li>
<li>First-degree relative with emphysema, bronhiectasis, panniculitis   </li>
</ul>
</li>
</ul>
<h3 id="exacerbation-prone-copd">Exacerbation-Prone COPD</h3>
<ul>
<li>Imaging phenotypes (Han MK, et al. Radiology 2011;261(1):274)   <ul>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503120342.png" />   </li>
</ul>
</li>
<li>COPDGene Study   <ul>
<li>Greater lung emphysema and airway wall thickness a/w COPD exacerbations, <strong>independent of the severity of airflow obstruction</strong>   </li>
</ul>
</li>
</ul>
<h1 id="pathophysiology">Pathophysiology</h1>
<h2 id="mucus-hypersecretion-ciliary-dysfunction">Mucus Hypersecretion &amp; Ciliary Dysfunction</h2>
<h3 id="mucus-hypersecretion">Mucus Hypersecretion</h3>
<ul>
<li>Results in chronic productive <a href="/not_created.html" class="nonexistent-link">cough</a>   <ul>
<li>Characteristic of chronic bronchitis but not necessarily a/w airflow obstruction   </li>
</ul>
</li>
<li>Not all patients with COPD have symptomatic mucous hypersecretion   </li>
<li>Hypersecretion is due to    <ul>
<li>squamous metaplasia   </li>
<li>increased # of goblet cells   </li>
<li>increased size of bronchial submucosal glands in response to chronic irritation by noxious particles and gases   </li>
</ul>
</li>
</ul>
<h3 id="ciliary-dysfunction">Ciliary Dysfunction</h3>
<ul>
<li>Ciliary Dysfunction due to   <ul>
<li>squamous metaplasia of epithelial cells   <ul>
<li>Abnormal mucociliary escalator   </li>
<li>Difficulty in expectorating   </li>
</ul>
</li>
</ul>
</li>
</ul>
<h2 id="airflow-limitation-air-trapping-hyperinflation">Airflow Limitation &amp; Air Trapping (Hyperinflation)</h2>
<ul>
<li>Inflammation, fibrosis, and luminal exudates occur in small airways (&lt;2 mm in diameter)   <ul>
<li>This is because of inflammation and narrowing (airway remodeling) and inflammatory exudates in the small airways   </li>
</ul>
</li>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503105202.png" />   </li>
<li>Number of small airways is decreased   <ul>
<li>smoking-related or may reflect abnormal early-life lung development   </li>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503105334.png" />   <ul>
<li>Hogg J. Lancet 2004; 364: 709–21   </li>
</ul>
</li>
</ul>
</li>
<li>Other factors -- loss of lung elastic recoil (due to destruction of alveolar walls) and destruction of alveolar support (from alveolar attachments)   </li>
<li><strong>Hyperinflation occurs early in the disease and is the main mechanism of exertional dyspnea</strong>   <ul>
<li>The progressive airway obstruction traps air during expiration resulting in   <ul>
<li>hyperinflation at rest   </li>
<li>dynamic hyperinflation during exercise   </li>
</ul>
</li>
<li>Reduces inspiratory capacity → reduction in FRC during exercise → breathlessness &amp; limited exercise capacity   </li>
</ul>
</li>
</ul>
<h2 id="emphysema-gas-exchange-abnormalities">Emphysema &amp; Gas Exchange Abnormalities</h2>
<ul>
<li>Peribronchiolar destruction of alveolar walls   </li>
<li>Loss of alveolar attachments   </li>
<li>Loss of elastic recoil and airway collapse   </li>
<li>Enlargement of air spaces   </li>
</ul>
<h3 id="subtypes-of-emphysema">Subtypes of Emphysema</h3>
<ul>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503112545.png" />   </li>
</ul>
<h3 id="gas-exchange-abnormalities">Gas Exchange Abnormalities</h3>
<ul>
<li>Gas exchange abnormalities occur in advanced disease   <ul>
<li>Arterial hypoxemia with or without hypercapnia   <ul>
<li>Anatomical changes in COPD → abnormal distribution of V/Q ratios → abnormal gas exchange   </li>
</ul>
</li>
<li>Extent of impairment of DLCO per liter of alveolar volume correlates well with the severity of emphysema   </li>
</ul>
</li>
</ul>
<h2 id="pulmonary-hypertension">Pulmonary Hypertension</h2>
<ul>
<li>Develops late in COPD at the time of severe gas exchange abnormalities   <ul>
<li>Hypoxia → pulmonary arterial constriction   </li>
<li>Structural change in pulmonary arterioles   <ul>
<li>Endothelial dysfunction   </li>
<li>Remodeling of pulmonary arteries (smooth muscle hypertrophy and hyperplasia)   </li>
<li>Destruction of pulmonary capillary bed   </li>
</ul>
</li>
</ul>
</li>
<li>Hypoxia + Structural changes in pulmonary arterioles → persistent pulmonary hypertension &amp; right ventricular hypertrophy or enlargement and dysfunction (cor pulmonale)   </li>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/2022-05-03%20copD02.f8.jpg" />   </li>
</ul>
<h2 id="systemic-effects">Systemic Effects</h2>
<ul>
<li>Systemic inflammation + skeletal muscle wasting → limited exercise capacity   <ul>
<li>worsen prognosis irrespective of degree of airflow obstruction   </li>
</ul>
</li>
<li>Increased risk of CV disease → a/w increase in CRP (see below)   </li>
</ul>
<h2 id="exacerbation-pathophysiology">Exacerbation Pathophysiology</h2>
<ul>
<li>Increased neutrophilic inflammation &amp; increased number of eosinophils (in mild exacerbations)   </li>
<li>Caused by infection, air pollution, and changes in ambient temperature   </li>
<li>Mild exacerbation   <ul>
<li>airflow obstruction is unchanged to slightly increased   </li>
</ul>
</li>
<li>Severe exacerbation   <ul>
<li>Worsening pulmonary gas exchange due to V/Q mismatch &amp; Respiratory Muscle Fatigue   </li>
<li>Worsening pulmonary gas exchange   <ul>
<li>airway inflammation, edema, mucous hypersecretion, and bronchoconstriction → reduce ventilation → hypoxic vasoconstriction of pulmonary arterioles → impairs perfusion   </li>
</ul>
</li>
<li>Respiratory Muscle Fatigue + Alveolar hypoventilation   <ul>
<li>Result in hypoxemia, hypercapnia, and respiratory acidosis → severe respiratory failure → death   </li>
<li>Hypoxia + Respiratory acidosis → pulmonary vasoconstriction → increase load on right ventricle + renal and hormonal changes → peripheral edema   </li>
</ul>
</li>
</ul>
</li>
</ul>
<h1 id="history-physical-examclinical-features">History &amp; Physical Exam/Clinical Features</h1>
<h1 id="diagnosis">Diagnosis</h1>
<h2 id="consider-copd-and-perform-spirometry-if">Consider COPD and Perform Spirometry if:</h2>
<ul>
<li><a href="/Pulmonary Medicine/12. Pulmonary Signs &amp; Symptoms/Dyspnea.html">Dyspnea</a> -- progressive over time, worse with exercise, persistent   </li>
<li>Chronic <a href="/Pulmonary Medicine/12. Pulmonary Signs &amp; Symptoms/Cough.html">Cough</a> -- may be intermittent and dry   </li>
<li>Recurrent <a href="/Pulmonary Medicine/12. Pulmonary Signs &amp; Symptoms/Wheezing.html">Wheezing</a>   </li>
<li>Chronic sputum   </li>
<li>Recurrent respiratory infections   </li>
<li>History of risk factors -- smoke or other noxious, occupational, genetics   </li>
<li>Childhood factors -- prematurity, maternal smoking, low birth weight   </li>
<li>Family history of COPD   </li>
<li>Presence or absence of symptoms (<a href="/Pulmonary Medicine/12. Pulmonary Signs &amp; Symptoms/Wheezing.html">Wheezing</a>, <a href="/Pulmonary Medicine/12. Pulmonary Signs &amp; Symptoms/Cough.html">Cough</a>, sputum production or <a href="/Pulmonary Medicine/12. Pulmonary Signs &amp; Symptoms/Dyspnea.html">Dyspnea</a>) was not particularly discriminative in diagnosing COPD in the general population   </li>
</ul>
<h2 id="gold-grades">GOLD Grades</h2>
<ul>
<li>Airflow limitation based on post-bronchodilator FEV₁   <ul>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503113106.png" />   </li>
<li><strong>Assess airflow limitation first then symptoms &amp; risk of exacerbation</strong>   </li>
</ul>
</li>
<li>FEV₁ and Mortality from NHANES 1 data   <ul>
<li>Increasing mortality with increasing severity of airflow limitation   </li>
<li>Never smokers with moderate-severe COPD were not at increased risk of mortality   </li>
</ul>
</li>
</ul>
<h2 id="symptom-assessment-tool">Symptom Assessment Tool</h2>
<h3 id="mmrc-dyspnea-scale">mMRC Dyspnea Scale</h3>
<ul>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503113302.png" />   </li>
</ul>
<h3 id="copd-assessment-tool-cat">COPD Assessment Tool (CAT)</h3>
<ul>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503113324.png" />   </li>
<li>8 items; scale 1-5   </li>
<li>Scores 0 - 40   <ul>
<li>&lt;10 - Low impact   </li>
<li>10-20 - Medium impact   </li>
<li>21-30 - High impact   </li>
<li>
<blockquote>
<p>30 - Very high impact   </p>
</blockquote>
</li>
</ul>
</li>
<li>Fixes limitation with predicting risk of acute exacerbation based on FEV₁   </li>
<li>Assess symptoms plus consequences (activity limitation, sleep, fatigue, self-efficacy)   </li>
</ul>
<h2 id="additional-investigations-to-consider">Additional Investigations to Consider</h2>
<ul>
<li>α-1 antitrypsin (AAT) screening   <ul>
<li>WHO recommends screening all patients with COPD at least once   </li>
</ul>
</li>
<li>Imaging   </li>
<li>Lung volumes and diffusing capacity   </li>
<li>Oximetry and blood gas measurement   </li>
<li>Exercise testing   </li>
<li>Composite scores (such as BODE index for COPD survival)   <ul>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503114500.png" />   </li>
<li>B- <strong>B</strong>MI, O- degree of airflow <strong>O</strong>bstruction (FEV₁%), D-<strong>D</strong>yspnea (mMRC), E-<strong>E</strong>xercise capacity index (6MWT)   </li>
<li>BODE is a better predictor of risk of death from any cause and from respiratory causes than is the FEV₁ alone   </li>
<li>FEV₁ does not adequately reflect all the systemic manifestations of the disease   <ul>
<li>FEV₁ correlates weakly with degree of dyspnea and change in FEV₁ does not reflect the rate of decline in patient's health   </li>
</ul>
</li>
<li>Degree of dyspnea and health-status scores are more accurate predictors of risk of death than is the FEV₁.   </li>
</ul>
</li>
<li>Biomarkers -- need further study   </li>
</ul>
<h2 id="diagnosis-of-aecopd">Diagnosis of AECOPD</h2>
<h1 id="management">Management</h1>
<h2 id="management-of-stable-copd">Management of Stable COPD</h2>
<ul>
<li>Goals of COPD Management   <ul>
<li>Reduce Symptoms   <ul>
<li>relieve symptoms of dyspnea   </li>
<li>improve exercise tolerance   </li>
<li>improve health status   </li>
</ul>
</li>
<li>Reduce Risk   <ul>
<li>prevent disease progression   </li>
<li>prevent and treat exacerbations   </li>
<li>reduce mortality   </li>
</ul>
</li>
</ul>
</li>
</ul>
<h3 id="pharmacologic-therapy">Pharmacologic Therapy</h3>
<ul>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503130532.png" />   </li>
<li>Symptomatic patients with mild to moderate COPD (post-bronchodilator FEV₁ ≥50% predicted), there is significant improvement of annual decline in FEV₁ after bronchodilator use, accompanied by a significant increase in the time to first AECOPD, <strong>but no improvement in mortality.</strong>   <ul>
<li>Improvement in prebronchodilator FEV₁ and post, mMRC and CAT scores   </li>
</ul>
</li>
<li>SABA and SAMA improve FEV₁ and symptoms   <ul>
<li>SABA + SAMA &gt; SABA or SAMA   </li>
</ul>
</li>
<li>LAMA and LABA improve lung function (FEV₁), dyspnea (symptoms), health status and exacerbations   <ul>
<li>LAMA -- greater effect on exacerbation and hospitalization reduction   </li>
<li>LAMA -- improve effectiveness of pulmonary rehabilitation   </li>
<li>LAMA + LABA &gt; LAMA or LABA   </li>
</ul>
</li>
<li>Inhaled Steroids   <ul>
<li>ICS + LABA -- more effective than ICS or LABA in improving lung function, health status and exacerbations   </li>
<li>Triple inhaled therapy (ICS/LABA/LAMA)   <ul>
<li>improves lung function, symptoms, health status, exacerbations, mortality vs   <ul>
<li>ICS/LABA or LABA/LAMA or LAMA   </li>
</ul>
</li>
</ul>
</li>
<li>Regular treatment with ICS increases risk of pneumonia, especially in those with severe disease   </li>
<li>Factors to consider when initiating ICS treatment   <ul>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503122636.png" />   </li>
</ul>
</li>
</ul>
</li>
<li>Data   <ul>
<li>ISOLDE Study (Burge PS, et al. BMJ. <strong>2000</strong>;320:1297)   <ul>
<li>ICS (Fluticasone) decreases COPD exacerbation risk by 25%   </li>
</ul>
</li>
<li>UPLIFT Study (Tashkin DP, et al. N Engl J Med. <strong>2008</strong>;359:1543)   <ul>
<li>LAMA (Tiotropium) decreases COPD exacerbation risk by 14%   </li>
</ul>
</li>
<li>TORCH Study (Calverley PM, et al. N Engl J Med. <strong>2007</strong>;356:775)   <ul>
<li>LABA + ICS (Salmeterol + Fluticasone) decreases COPD exacerbation more than ICS or LABA alone   </li>
</ul>
</li>
<li>POET-COPD Study (Vodelmeier et al. NEJM <strong>2011</strong>;364:1093)   <ul>
<li>LAMA (Tiotropium) decreases exacerbations more than LABA (Salmeterol)   </li>
</ul>
</li>
<li>FLAME Study (Wedzicha et al. NEJM <strong>2016</strong>; 374: 2222)   <ul>
<li>LAMA + LABA (Glycopyrronium + Indacaterol) decreases exacerbations more than ICS + LABA (Fluticasone + Salmeterol)   </li>
<li>Effect independent of baseline blood eosinophil count   </li>
<li>Higher incidence of pneumonia in ICS group   </li>
</ul>
</li>
<li>ETHOS Study (Rabe et al. NEJM <strong>2020</strong>; 383:35) -- looked at exacerbation rate   <ul>
<li>Large study - 8509 patients with moderate to very severe COPD   <ul>
<li>≥1 moderate to severe exacerbation in prior year if FEV₁ &lt;50%   </li>
<li>≥2 moderate or ≥1 severe exacerbation if FEV₁ 50-65%   </li>
</ul>
</li>
<li>ICS used was Budesonide 160 and 320   </li>
<li>Triple therapy with Budesonide 160 had lowest rate of moderate to severe exacerbation compared to triple therapy with Budesonide 320 and ICS + LABA and LAMA + LABA (highest rate) -- surprising that LAMA + LABA had a higher exacerbation rate than ICS + LABA when FLAME study said opposite (potentially a result of the individual drugs used?)   </li>
</ul>
</li>
<li>IMPACT Study (Lipson et al. AJRCCM <strong>2020</strong>) -- looked at mortality   <ul>
<li>Large study - 10355 patients with symptomatic COPD; FEV₁ &lt;50% and at least 1 moderate to severe exacerbation in the prior year; FEV₁ 50 - &lt;80% and at least 1 severe or 2 moderate exacerbations (a little higher cut off than ETHOS study)   </li>
<li>LAMA + LABA highest all-cause mortality   </li>
<li>ICS + LABA &amp; triple therapy had similar all-cause mortality at the end of 52 weeks   </li>
</ul>
</li>
<li>Macrolide Therapy in COPD &amp; Exacerbations   <ul>
<li>Long-term macrolide therapy reduces exacerbations (Seemungal et al. AJRCCM 2008)   <ul>
<li>medium time to 1st exacerbation 271 days macrolide; 89 days for placebo   </li>
</ul>
</li>
<li>Azithromycin therapy (Albert et al NEJM 2011; 365:689)   <ul>
<li>medium time to exacerbation 266 days azithromycin; 174 days placebo   </li>
</ul>
</li>
</ul>
</li>
<li>Roflumilast &amp; Exacerbations (Martinez et al Lancet 2015;385:857)   <ul>
<li>All patients had baseline LABA/ICS use   </li>
<li>13% reduction in exacerbations   </li>
</ul>
</li>
</ul>
</li>
</ul>
<h3 id="non-pharmacologic-therapy">Non-Pharmacologic Therapy</h3>
<ul>
<li>Smoking cessation   <ul>
<li>Effect on Lung Function (The Lung Health Study at 11 years Anthonisen et al. Am J Respir Crit Care Med. 2002;166:675)   <ul>
<li>Men who quit had an FEV₁ rate of decline of 30 mL/year   </li>
<li>Men who continued to smoke had an FEV₁ rate of decline of 66 mL/year   </li>
</ul>
</li>
<li>Effect on Lung Function (The Lung Health Study at 14 years Anthonisen NR, et al. Ann Intern Med. 2005;142:233)   <ul>
<li>Sustained quitters had the least deaths per 1000 person-years followed by intermittent quitters and highest deaths per 1000 person-years for continued smokers   </li>
</ul>
</li>
</ul>
</li>
<li>Immunization   <ul>
<li>Influenza vacciantion reduces serious illness and death in COPD patients   </li>
<li>PPSV 23 has been shown to reduce the incidence of CAP in    <ul>
<li>COPD patients aged &lt;65 years + FEV₁ &lt;40% predicted   </li>
<li>Those with comorbidities   </li>
</ul>
</li>
<li>PCV 13 demonstrated significant efficacy in reducing bacteremia and serious invasive pneumococcal disease in adults ≥65 years   <ul>
<li>No longer recommended by CDC unless specific risk factors   </li>
</ul>
</li>
<li>Tdap vaccination recommended in adults with COPD who were not vaccinated in adolescence to protect against pertussis   </li>
</ul>
</li>
<li>Pulmonary rehabilitation (Alison et al. Respirology 2017;22(4):800 McCarthy et al. Cochrane Database of Systematic Reviews 2015, Issue 2. Art. No.: CD003793)   <ul>
<li>Significantly improves exercise capacity and health status (QOL/anxiety/depression/dyspnea)   </li>
<li>Reduces frequency of exacerbations   </li>
<li>Reduces the number of readmissions in the year following initiation   </li>
<li>Reduction in mortality   </li>
<li>Optimum benefit from programs 6-8 weeks' duration   </li>
<li><strong>does not improve pulmonary function tests or oxygenation</strong>   </li>
</ul>
</li>
<li>Oxygen therapy   <ul>
<li>Long-term oxygen therapy (LTOT) = &gt;15 hours/day   </li>
<li>Severe chronic resting arterial hypoxemia (PaO₂ ≤55 mm Hg)   <ul>
<li>Long-term oxygen therapy <strong>improved survival</strong> vs nocturnal-only or no oxygen   </li>
</ul>
</li>
<li>Moderate chronic resting hypoxemia (PaO₂ 56-59 mm Hg or SpO₂ 88-90%) + cor pulmonale or polycythemia   <ul>
<li>Long-term oxygen therapy <strong>improved survival</strong>   </li>
</ul>
</li>
<li>Moderate chronic resting hypoxemia (SpO₂ 89-93%)   <ul>
<li>Long-term oxygen therapy <strong>does not</strong> lengthen time to death or time to first hospitalization or provide sustained benefit in health status, lung function and 6MWT distance   </li>
</ul>
</li>
<li>Exercise-Induced Hypoxemia (SpO₂ during 6MWT ≥80% for ≥5 minutes and &lt;90% for ≥10 seconds)   <ul>
<li>Long-term oxygen therapy <strong>does not</strong> lengthen time to death or time to first hospitalization or provide <strong>sustained</strong> benefit in health status, lung function and 6MWT distance   <ul>
<li>Use of supplemental oxygen during exercise, however, increases exercise performance   </li>
</ul>
</li>
<li>SpO₂ 80 to 88% during exercise (Moderate Exercise Hypoxemia), → O₂ during exercise did not improve long term outcomes of hospitalization, QOL, dyspnea   <ul>
<li>Supplemental oxygen may remove the stimulus to hypoxia-compensating mechanisms such as those seen in residents of high-altitude   </li>
</ul>
</li>
</ul>
</li>
<li>Indications in Stable COPD   <ul>
<li>Resting Hypoxemia   <ul>
<li>PaO₂ ≤55 mm Hg or SaO₂ ≤88%   </li>
<li>PaO₂ ≤59 mm Hg or SaO₂ ≤ 89% +    <ul>
<li>EKG evidence of cor pulmonale   </li>
<li>Hematocrit &gt; 55   </li>
<li>Clinical evidence of right heart failure   </li>
</ul>
</li>
</ul>
</li>
<li>Exercise-Induced Hypoxemia   <ul>
<li>PaO₂ ≤55 mm Hg during exercise (Severe Exercise Hypoxemia) → O₂ prescribed for use DURING exercise   <ul>
<li>Unknown if this has any effect on long-term outcome benefits   </li>
<li>Use during exercise did not translate to improvement/benefit in dyspnea or ADLs when not using oxygen   </li>
</ul>
</li>
</ul>
</li>
<li>Sleep-Induced Hypoxemia   <ul>
<li>PaO₂ ≤55 mm Hg during sleep → O₂ prescribed   </li>
<li>Also need to evaluate with PSG for underlying sleep-disordered breathing   </li>
</ul>
</li>
</ul>
</li>
<li>Supplemental oxygen sometimes provides symptomatic dyspnea relief by stimulating a decrease in minute ventilation → may improve activity but does not improve survival   </li>
<li>COPD + DOE can be from exertional hypoxemia but also from mechanical loading of the respiratory system, deconditioning and concomitant cardiac disease → pulmonary rehabilitation   </li>
</ul>
</li>
<li>Non-invasive positive pressure ventilation   <ul>
<li>In stable hypercapnic COPD improves survival (Kohnlein et al. Lancet Respir Med 2014;2:698)   </li>
<li>Criteria: GOLD stage IV COPD + PaCO₂ ≥ 52 mm Hg &amp; pH &gt; 7.35   </li>
<li>Long-term NPPV targeted to reduce hypercapnia   </li>
<li>11% reduction in mortality at 1 year   </li>
<li>In patients admitted for AECOPD requiring NIV and who remain hypoxemic and hypercarbic (PaCO₂ ≥52 mm Hg) 2 weeks following discharge, the addition of goal-directed <strong>nocturnal NIV</strong> to continous O₂ has been shown to significantly <strong>prolong time to hospital readmission and death within 12 months</strong> + improved health-related QOL and reduction in AECOPD frequency   <ul>
<li>AECOPD + NIV = poor prognosis w/ median time to readmission or death less than a year   <ul>
<li>benefit from supplemental oxygen   </li>
<li>use NIV for at least 6 hours at night → reduce nocturnal hypoventilation → reduction in daytime PaCO₂ by 6-8 mm Hg   </li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Interventional &amp; Surgical Therapy in Stable COPD   </p>
<ul>
<li>Surgical Lung Volume Reduction (NETT research group NEJM 2003;348:2059 Naunheim et al. Ann Thorac Surg 2006; 82:431)   <ul>
<li>Upper lobe emphysema a/w improvement in exercise capacity &amp; QOL   </li>
<li>Upper lobe emphysema + low baseline exercise capacity a/w improvement in survival   </li>
</ul>
</li>
<li>Bronchoscopic Lung Volume Reduction w/ Endobronchial Valves (EBV) (Criner et al. AJRCCM 2018;198(9):1151 Kemp et al. AJRCCM 2017;196(12):1535 Majid et al. Respiration 2020;99(1):62)   <ul>
<li>Criteria   <ul>
<li>hyperinflation due to severe emphysema   </li>
<li>symptomatic despite optimal medical therapy and pulmonary rehabilitation   </li>
</ul>
</li>
<li>EBV placed in lung region with most emphysematous destruction and <strong>no collateral ventilation</strong>   </li>
<li>Zephyr duckbill shaped and Spiration umbrella-shaped EBV approved in USA   </li>
<li>Efficacy -- <strong>improved FEV₁, dyspnea, 6MWD, QOL, RV</strong>   </li>
<li>A/E -- significant risk of pneumothorax (25-30%)   </li>
<li>EBV does not preclude subsequent LVRS or transplant <br />
| Reduce Exacerbations              | Reduce Mortality             | <br />
| --------------------------------- | ---------------------------- | <br />
| LABA, LAMA, LABA + LAMA           | <strong>LABA + LAMA + ICS</strong>        | <br />
| LABA + ICS, <strong>LABA + LAMA + ICS</strong> | <strong>Smoking Cessation</strong>        | <br />
| Roflumilast                       | <strong>LVRS</strong>                     | <br />
| Chronic macrolide                 | NIPPV                        | <br />
| <strong>Smoking Cessation</strong>             | <strong>Pulmonary Rehabilitation</strong> |  <br />
| Vaccines                          |                              | <br />
| <strong>Pulmonary Rehabilitation</strong>      |                              | <br />
| <strong>LVRS</strong>                          |                              | <br />
| N-acetylcysteine                  |                              | <br />
| Vitamin D                         |                              |   </li>
</ul>
</li>
</ul>
</li>
<li>
<p><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503131525.png" />   </p>
</li>
</ul>
<h2 id="management-of-acute-exacerbations">Management of Acute Exacerbations</h2>
<ul>
<li>SABA with or without SAMA are recommended as initial bronchodilators   </li>
<li>Systemic corticosteroids improve FEV₁, oxygenation and shorten recovery time and duration of hospitalization   <ul>
<li>Duration of therapy no more than 5-7 days   </li>
</ul>
</li>
<li>Antibiotics if signs of bacterial infection   <ul>
<li>shorten recovery time, reduce risk of early relapse and treatment failure, reduce hospital duration   </li>
</ul>
</li>
<li>Methylxanthines not recommended   </li>
<li>NIV for AECOPD   <ul>
<li>If no contraindication, NIV in patients with acute respiratory failure 2/2 AECOPD   <ul>
<li>improves gas exchange   </li>
<li>reduces work of breathing   </li>
<li>reduces need for intubation   </li>
<li>reduces hospital duration and hospital re-admission   </li>
<li>improves survival   </li>
</ul>
</li>
</ul>
</li>
</ul>
<h1 id="complication-prognosis">Complication &amp; Prognosis</h1>
<ul>
<li>Diagnosed COPD   <ul>
<li>Asymptomatic individuals with FEV₁ &lt;80% (moderate or more severe obstruction) experience significant adverse events similar to symptomatic COPD   </li>
</ul>
</li>
<li>Undiagnosed COPD   <ul>
<li>Symptomatic individuals with undiagnosed COPD were found to have an increased risk of exacerbations, pneumonia and death   </li>
<li>Asymptomatic individuals with undiagnosed COPD had an increased risk of exacerbations and pneumonia   </li>
</ul>
</li>
</ul>
<h2 id="comorbidities-4e379d">Comorbidities ^4e379d</h2>
<ul>
<li>Heart failure - prevalence 20-70%   </li>
<li>CAD - increased risk of MI for 30 days after acute exacerbation of chronic bronchitis (AECB)   <ul>
<li>COPD is an independent risk factor for CV disease   <ul>
<li>increased the odds of having CV disease by 2.7   </li>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503115607.png" />    <ul>
<li>Finkelstein J, et al. Int J Chron Obstruct Pulmon Dis. 2009;4:337   </li>
</ul>
</li>
</ul>
</li>
<li>Effects of airflow obstruction and systemic inflammation are additive   <ul>
<li>Increase in cardiac infarction injury score as airflow obstruction gets worse   </li>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503115800.png" /> (Sin    <ul>
<li>DD &amp; Man SF. Circulation 2003; 107: 1514   </li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>PVD - higher prevalence in COPD (8.8% vs 1.8%)   </li>
<li>Osteoporosis - associated with emphysema, low BMI, low fat-free mass   <ul>
<li>Severity of airflow obstruction predicts osteoporosis   </li>
<li>Worsening severity of airflow obstruction -&gt; increasing percentage of osteoporosis   <ul>
<li>More prominent in women than men   </li>
</ul>
</li>
</ul>
</li>
<li>Metabolic syndrome - prevalence &gt;30%   </li>
<li>GERD - independent risk factor for exacerbations   </li>
<li>OSA overlap with COPD a/w worse prognosis   </li>
</ul>
<h3 id="impact-on-mortality">Impact on Mortality</h3>
<ul>
<li>Estimated age-adjusted mortality a/w selected comorbid conditions   </li>
<li>Holguin et al. CHEST 2005;128(4):2005 - National Hospital Discharge Survey 1979-2001; 47 million discharges   </li>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503120027.png" />   <ul>
<li>Those with COPD and comorbid condition had higher in-hospital mortality from the percentage of people that were discharged   </li>
</ul>
</li>
</ul>
<h3 id="frequent-exacerbations-decline-in-lung-function">Frequent Exacerbations &amp; Decline in Lung Function</h3>
<ul>
<li>More exacerbations = faster decline in lung function   </li>
<li>Donaldson GC, et al. Thorax. 2002;57:847   </li>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503121045.png" />   </li>
<li>PEFR recovery after exacerbation (Seemungal TA, et al. Am J Respir Crit Care Med. 2000;161:1608)   <ul>
<li>Recovery of PEFR to baseline values was complete in only 75% of exacerbations at 35 day   </li>
<li>In 7% of exacerbations at 91 days PEFR recovery had not occurred   </li>
</ul>
</li>
</ul>
<h3 id="copd-exacerbations-impact-survival">COPD Exacerbations Impact Survival</h3>
<ul>
<li>Severe COPD Exacerbations   <ul>
<li>Soler-Cataluña JJ et al Thorax 2005;64:925   </li>
<li>304 male patients, hospitalized for AECOPD followed for 5 years   </li>
<li>Risk of death 4.3 times greater in frequent exacerbators   </li>
<li><img alt="" src="/Pulmonary%20Medicine/01.%20Diseases%20of%20the%20Airways/attachments/Pasted%20image%2020220503121148.png" />   </li>
</ul>
</li>
<li>In general exacerbations are a/w increased mortality   <ul>
<li>In patients hospitalized with AECOPD   <ul>
<li>14% mortality in 3 months   </li>
<li>28% mortality in 1 year   </li>
</ul>
</li>
<li>If AECOPD w/ PaCO₂ &gt; 50 mm Hg, a/w   <ul>
<li>33% mortality in 6 months   </li>
<li>43% mortality in 12 months   </li>
</ul>
</li>
<li>Roberts et al. Thorax 2002;57(2):137 Connors et al. AJRCCM 1996; 154(4):959 Slenter et al. Respiration 2013;85(1):15 Almagro et al. Respiration 2012;84(1):36</li>
</ul>
</li>
</ul><h2>Backlinks</h2>
<ul>
	<li><a class="backlink" href="/Pulmonary Medicine/01. Diseases of the Airways.html">01. Diseases of the Airways</a></li>
	<li><a class="backlink" href="/Pulmonary Medicine/01. Diseases of the Airways/Chronic Obstructive Pulmonary Disease.html">Chronic Obstructive Pulmonary Disease</a></li>
</ul>
<script src="/obs.html/static/graph.js" type="text/javascript"></script>

<div class="graph">
    <div id="A15373459183877847209291243916980199291{level}" class="graph_div"></div>
    <button class="graph_button" id="B15373459183877847209291243916980199291{level}" level="{level}" onclick="run('15373459183877847209291243916980199291'+this.level, 'Chronic Obstructive Pulmonary Disease');">Show Graph</button>
</div>


<script src="//unpkg.com/3d-force-graph"></script>
<script>
    function grapher(args) {
        window.Graph = ForceGraph3D()
            (args.graph_container)
            .jsonUrl(args.data)
            .width(args.width)
            .height(args.height)
            .nodeLabel('id')
            .linkDirectionalParticles("value")
            .linkDirectionalParticleSpeed(0.010)
            .linkDirectionalParticleWidth(2.0)
            .nodeColor(node => {
                if (node.id == current_node_id){
                    return '#ff0000'
                }
                let isConnected = false;
                node.links.forEach(link => {
                    if (link == current_node_id){
                        isConnected = true;
                    }
                })
                if (isConnected){
                    return '#f7be49';
                }
                return '#ffffff'
            })
            .linkColor(link => {
                if (link.source == current_node_id || link.target == current_node_id){
                    return '#ff0000'
                }
                return '#dadada'
            })
            .linkOpacity(0.3)
            .onNodeClick(node => {
                args.node = node;
                graph_left_click(args)()
            })
            .onNodeRightClick(node => {
                args.node = node;
                graph_right_click(args)()
            });
    }
</script>


                        <!-- end content -->
                        </div>
                        <div id="right_pane"></div>
                </div>
        </div>

<script src="/obs.html/static/obsidian_core_footer.js" type="text/javascript"></script>
<script src="/obs.html/static/load_dirtree_footer.js" type="text/javascript"></script>


</body>
</html>
